Risk Adapted Therapy of Hodgkin Lymphoma in Upper Egypt

Assiut University

Status: Not yet enrolling

Conditions: Pediatric Hodgkin Lymphoma

Treatments: Radiation: radiotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT06340243

HODGKIN

Details and patient eligibility

About

determine if radiotherapy could be safely omitted for early hodgkin lymphoma responder patients without compromising outcome

Full description

Hodgkin's lymphoma accounts for around 40% of all pediatric lymphomas and is the most prevalent cancer among adolescents and young adults. With combinations of chemotherapy and radiation, Hodgkin's lymphoma is roughly 80% curable, placing it among the most treatable cancers . Since the introduction of combination chemotherapy treatments 20 years ago, the prognosis for children with Hodgkin's lymphoma has improved. The treatment is mostly influenced by the stage of the disease at diagnosis, histology, existence of "B"-symptoms, and the presence of bulky disease. Nonetheless, 20% of patients do not achieve long-term remission, and around 20% experience treatment-related side effects such as secondary malignancies, infertility, cardiovascular disease, and organ malfunction following chemo-radiation .Studies of long-term therapy side effects were made possible by the significant number of survivors. The goal of therapy optimization protocols for pediatric patients with Hodgkin's lymphoma is to maintain excellent tumor control while limiting adverse effects and long-term consequences . It is critical to stratify patients based on reliable prognostic factors at presentation and according to the rapidity of response into low-risk (LR) patients who would benefit from less aggressive therapy, avoiding unnecessary toxic side effects, and high-risk (HR) patients who should be subjected to intensified therapy to reduce the rate of treatment failures and relapses .

Enrollment: 50 estimated patients

Sex: All

Ages: 1 month to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Previously untreated patients younger than 18 years old with classical Hodgkin lymphoma

Exclusion criteria

• Patients aged more than 18 years old.
• Patients who died early at presentation before starting chemotherapy
• diagnosis of nodular lymphocytic predominant Hodgkin lymphoma
• previous chemotherapy or radiotherapy other (simultaneous) malignancies
• severe concomitant diseases (eg, immune deficiency syndrome); or known HIV positive.